Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Thermo Fisher Scientific Inc / Equity Bottom-Up

<ul><li>Thermo Fisher had a good quarter and delivered an all-around beat as a result of the fact that its core business has been robust.</li><li>Excellent growth has been viewed over every business, highlighted by its pharma services and bioproduction businesses.</li><li>We provide the stock of Thermo Fisher with a ‘Hold’ rating with a revision in the target price.</li></ul>

Thermo Fisher had a good quarter and delivered an all-around beat as a result of the fact that its core business has been robust.Excellent growth has been viewed over every business, highlighted by its pharma services and bioproduction businesses.We provide the stock of Thermo Fisher with a ‘Hold’ rating with a revision in the target price.

Thermo Fisher Scientific: New Product Launches & Other Drivers

Equity Capital Markets

Thermo Fisher Scientific Inc / Equity Capital Markets

<ul><li>Thermo Fisher Scientific had a strong start to 2022, with its core business performing well.</li><li>Thermo Fisher was able to gain market share and deliver a strong execution.</li><li>The company viewed a strong growth in the healthcare market channel, transparent diagnostics, and clinical diagnostics in the core business.</li></ul>

Thermo Fisher Scientific had a strong start to 2022, with its core business performing well.Thermo Fisher was able to gain market share and deliver a strong execution.The company viewed a strong growth in the healthcare market channel, transparent diagnostics, and clinical diagnostics in the core business.

Thermo Fisher Scientific Inc: New Product Launches & Other Key Drivers

Credit

<ul><li>Thermo Fisher has had an excellent growth strategy driven by a combination of organic and inorganic growth, powered by their PPI business system.</li><li>The company achieved 17% organic growth for 2021, with 14% organic base business growth and $9.2 billion in Covid-19 response revenue.</li><li>Based on our credit analysis, the company merits a Credit Evaluation Score of BBβ with a stable outlook and as per our Financial Strength Indicator, its performance is 3.91/ 5.</li></ul>

Thermo Fisher has had an excellent growth strategy driven by a combination of organic and inorganic growth, powered by their PPI business system.The company achieved 17% organic growth for 2021, with 14% organic base business growth and $9.2 billion in Covid-19 response revenue.Based on our credit analysis, the company merits a Credit Evaluation Score of BBβ with a stable outlook and as per our Financial Strength Indicator, its performance is 3.91/ 5.

Thermo Fisher Scientific Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report

<ul><li>Thermo Fisher delivered yet another decent quarter re-emphasizing the effectiveness of their growth strategy, powered by their PPI business system.</li><li>The company achieved 17% organic growth for the full year of 2021, with 14% organic base business growth and $9.2 billion in COVID-19 response revenue.</li><li>Throughout the year, Thermo Fisher experienced strong growth in a number of areas, including biosciences, electron microscopy, and its research and safety market channel.</li></ul>

Thermo Fisher delivered yet another decent quarter re-emphasizing the effectiveness of their growth strategy, powered by their PPI business system.The company achieved 17% organic growth for the full year of 2021, with 14% organic base business growth and $9.2 billion in COVID-19 response revenue.Throughout the year, Thermo Fisher experienced strong growth in a number of areas, including biosciences, electron microscopy, and its research and safety market channel.

Thermo Fisher: A True One-Stop Shop For All Life Science Needs 02/22

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>New Covid cases across the world is surging. New Covid-19 variant found in South Africa and Botswana is adding to fears.</li>
<li>This will bring the focus back to molecular diagnostic companies due to increasing demand for Covid testing.</li>
<li>We have listed few global diagnostic companies, which should benefit from this backdrop.</li>
</ul>


New Covid cases across the world is surging. New Covid-19 variant found in South Africa and Botswana is adding to fears.
This will bring the focus back to molecular diagnostic companies due to increasing demand for Covid testing.
We have listed few global diagnostic companies, which should benefit from this backdrop.


New Covid Variant Raises Fear: Stocks to Own to Buck the Trend

United States

Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Thermo Fisher Scientific (TMO UN)

Thermo Fisher Scientific: New Product Launches & Other Drivers

Thermo Fisher had a good quarter and delivered an all-around beat as a result of the fact that its core business has been robust. Excellent growth...

Baptista Research

Thermo Fisher Scientific Inc: New Product Launches & Other Key Drivers

Thermo Fisher Scientific had a strong start to 2022, with its core business performing well. Thermo Fisher was able to gain market share and...

Baptista Research

Thermo Fisher Scientific Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report

Thermo Fisher has had an excellent growth strategy driven by a combination of organic and inorganic growth, powered by their PPI business...

Baptista Research

Thermo Fisher: A True One-Stop Shop For All Life Science Needs 02/22

Thermo Fisher delivered yet another decent quarter re-emphasizing the effectiveness of their growth strategy, powered by their PPI business...

Baptista Research

New Covid Variant Raises Fear: Stocks to Own to Buck the Trend

Amidst the rising fear for the new Covid variant, investors can focus on molecular diagnostic stocks, as testing demand will be increasing again.

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)